History
A scientific legacy spanning two decades
With the company’s founding roots in Scil Group, an offshoot of Boehringer Mannheim, Formycon’s organization and biopharmaceutical development expertise date back much farther than its name.
- SARS-CoV-2 drug FYB207 shows longer half-life and improved efficacy
- Formycon publishes details of pipeline project FYB206
- European Commission approves FYB201
- Formycon’s Biosimilar Ustekinumab Candidate FYB202 shows comparable efficacy to reference product Stelara® in Phase III Study
- FDA approved FYB201/CIMERLI™ (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®
- Formycon publishes update on Development Projects
- Formycon Reports First Quarter 2022 Financial Results and Announces Development Start of two New Biosimilar Candidates FYB208 and FYB209
- Formycon appoints Dr. Stefan Glombitza as CEO and appoints Nicola Mikulcik and Dr. Andreas Seidl to the Executive Board
- United Kingdom Medicines and Healthcare Products Regulatory Agency MHRA grants Marketing Authorization for FYB201, Formycon’s Biosimilar for Lucentis®¹
- Formycon AG and ATHOS KG announce closing of transaction to acquire biosimilar assets FYB201 and FYB202 as well as Bioeq GmbH
- Formycon and ATHOS KG merge development activities in a long-term strategic partnership
- MS Pharma becomes exclusive partner for the commercialization of FYB201 in the MENA region
- Formycon and Scientists from TUM publish new Data on FYB207
- Formycon and SCG Cell Therapy announce Collaboration and License Agreement for FYB207
- Formycon and Bioeq announce File Acceptance for FYB201 by the FDA
- Formycon’s COVID-19 drug FYB207 wins Pharma Trend Image & Innovation Award
- Formycon and Bioeq announce submission of the biologics license application to the FDA
- Formycon receives Euro 12.7 million grant for further development of FYB207
- Formycon and Bioeq announce submission of the marketing authorization application for FYB201 to the EMA
- Teva Pharmaceutical becomes strategic partner for the commercialization of FYB201 in Europe, Canada, Israel and New Zealand
- Formycon’s COVID-19 Drug FYB207 even more efficient against SARS-CoV-2 Mutant B.1.1.7
- Formycon receives positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207
- Innovative SARS-CoV-2-Blocker from Formycon completely prevents infection of cells
- Chief Operating Officer Dr. Stefan Glombitza appointed to Formycon’s Management Board for another four years
- Formycon and Bioeq announce launch of phase III study with ustekinumab biosimilar candidate FYB202
- Formycon informs about the modified BLA-submission strategy for its Lucentis® Biosimilar-Candidate FYB201
- Formycon receives funding for COVID-19 drug research from the Bavarian Research Foundation
- Formycon places cash capital increase of 25.75 Million Euros with strategic investor
- Formycon and Bioeq enroll first patient in phase III study with aflibercept biosimilar (FYB203)
- Formycon starts antibody-based drug development for COVID-19
- Formycon informs about current status of the BLA review process of the Lucentis® Biosimilar-Candidate FYB201
- Bioeq IP AG exclusively licenses US Marketing Rights for FYB201 to Coherus BioSciences, Inc.
- Formycon announces start of phase I clinical trial with ustekinumab biosimilar candidate FYB202
- Formycon places cash capital increase of EUR 17.3 Million with institutional investor
- Formycon appoints development and production expert Thomas Siklosi to the Advisory Board
- Biosimilar candidate FYB201 shows efficacy comparable to the reference product in clinical phase III
- Formycon ranks 7th in the Financial Times list of Europe’s 1000 strongest-growing companies
- Formycon and Aristo Pharma establish joint venture for FYB202
- Pipeline news: FYB202 is a biosimilar candidate for Stelara®
- Formycon changes in new SME stock exchange segment “Scale”
- Focus magazine lists Formycon as growth champion 2017
- German Stifterverband awards Formycon for innovative strength
- Santo Holding (Deutschland) GmbH tranfers global commercialization rights for FYB201 to Bioeq IP AG
- Dr. Carsten Brockmeyer again honored as one of the most influential people in medicines industry
- Expansion of product pipeline with fourth biosimilar candidate
- Details on FYB203: Formycon develops biosimilar for Eylea® (aflibercept)
- Appointment of biotech expert Professor Johannes Buchner to Advisory Board
- Enrollment of first patient in pivotal phase III study with Lucentis® biosimilar (FYB201)
- Formycon and Bioeq initiate pivotal phase III clinical trial with Lucentis® biosimilar (FYB201)
- Out-licensing of second biosimilar to Santo Holding
- Medicine Maker: Dr. Carsten Brockmeyer under Top 20 in medicines industry
- Capital increase of EUR 11.1 million
- Successful GMP inspection
- Development of third biosimilar begins
- Leading East European pharmaceutical manufacturer Polpharma joins FYB201 project as a joint venture partner
- Formycon AG appoints top US pharmaceuticals manager Bernhard Hampl to the Advisory Board
- Successful completion of capital increase totaling EUR 17.5 million
- Start of development of first and second product
- Out-licensing of first biosimilar from Formycon product Pipeline to Santo Holding GmbH
- Renaming to Formycon AG
- Leadership in the development of high-quality biopharmaceutical follow-up-products
- 2011: Scil Technology GmbH licenses its flagship project to Sanofi
- 2010: Scil Technology GmbH establishes a dedicated research and services unit under the name “Formycon”
- 2008: Scil Technology GmbH licenses project portfolio to Medtronic
- 2003: Alongside its own R&D projects, Scil Technology GmbH wins its first service-provider contracts, conducting its first biosimilar development projects on behalf of clients
- 2001: Analytical laboratory receives GMP certification
- 1999: Former executives of Boehringer Mannheim found Scil Technology GmbH